Alembic Ltd

₹ 113 -0.71%

13 Nov - close price

alembiclimited.com BSE: 506235 NSE: ALEMBICLTD

About

Alembic Limited is engaged in the businesses of Pharmaceuticals, Real Estate, and Power Assets. The company was started in 1907 as the flagship company of the Alembic Group. In 2010, the company demerged its core pharmaceutical business (formulations) into a wholly-owned subsidiary, Alembic Pharma Ltd and after the demerger, APL became the flagship company of the Alembic Group.
With its registered office in Vadodra, Alembic Ltd currently holds a 28.41% stake in Alembic Pharma Ltd and a 19.01% stake in another group entity Paushak Limited.^[1]

Key Points

Business Segments:^[1]
a) Real Estate (81% in FY26 vs 85% in FY25):^[2]
The company develops residential and commercial real estate projects, provides
project management and marketing consultancy services and generates rental income by leasing commercial properties.

Website BSE NSE

Market Cap ₹ 2,914 Cr.
Current Price ₹ 113
High / Low ₹ 118 / 70.5
Stock P/E 8.21
Book Value ₹ 104
Dividend Yield 2.12 %
ROCE 6.07 %
ROE 13.0 %
Face Value ₹ 2.00

Add ratio to table

Edit ratios

Pros

Company has reduced debt.
Company is almost debt free.
Stock is trading at 1.09 times its book value
Company has been maintaining a healthy dividend payout of 20.7%

Cons

Company has a low return on equity of 13.1% over last 3 years.
Earnings include an other income of Rs.82.0 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Consumer Discretionary Realty Realty Residential, Commercial Projects

Part of BSE Consumer Discretionary BSE 1000

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
	32	39	49	51	53	58	60	50	56	74	60	49	30
YoY Sales growth	-14%	+28%	+32%	+38%	+64%	+47%	+23%	-2%	+6%	+28%	-0%	-2%	-46%
	22	28	25	30	33	32	33	30	33	47	40	33	25
Operating Profit	10	12	24	20	20	26	27	20	23	27	20	15	5
OPM %	31%	30%	49%	40%	37%	46%	45%	39%	42%	37%	34%	32%	17%
	48	2	2	2	66	4	3	4	65	2	2	6	72
Interest	0	0	0	0	1	1	1	1	1	1	1	1	1
Depreciation	2	3	1	2	3	3	3	3	3	3	3	3	4
Profit before tax	56	11	24	19	82	27	27	20	85	26	18	17	73
Tax %	8%	9%	12%	10%	6%	5%	12%	10%	10%	13%	48%	9%	7%
	91	61	72	56	121	65	68	62	128	60	67	65	163
EPS in Rs	3.53	2.39	2.81	2.17	4.71	2.55	2.67	2.40	5.00	2.34	2.61	2.53	6.34
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	144	134	147	125	124	74	74	78	127	157	222	240	213
Sales growth		-7%	+10%	-15%	-1%	-40%	-1%	+6%	+63%	+24%	+41%	+8%	-5%
	134	128	140	114	106	71	62	64	87	101	128	150	145
Operating Profit	10	6	7	11	18	3	11	14	40	57	94	90	68
OPM %	7%	4.6%	4.6%	9%	15%	4.4%	15%	18%	32%	36%	42%	38%	32%
	21	25	25	37	29	93	10	89	54	55	75	73	82
Interest	1	0	0	0	0	0	0	0	0	1	2	2	2
Depreciation	6	6	5	4	3	3	4	5	7	8	11	12	14
Profit before tax	23	25	27	44	45	93	17	98	87	103	156	149	134
Tax %	-3%	2%	-3%	5%	8%	0%	19%	12%	7%	10%	7%	15%
	107	235	145	163	213	329	343	222	191	269	311	317	355
EPS in Rs	3.99	8.78	5.45	6.10	8.30	12.82	13.35	8.65	7.42	10.46	12.10	12.36	13.82
Dividend Payout %	4%	2%	4%	3%	2%	5%	2%	21%	30%	23%	20%	19%

Compounded Sales Growth
10 Years:	6%
5 Years:	27%
3 Years:	24%
TTM:	-5%

Compounded Profit Growth
10 Years:	3%
5 Years:	-2%
3 Years:	16%
TTM:	10%

Stock Price CAGR
10 Years:	15%
5 Years:	0%
3 Years:	12%
1 Year:	12%

Return on Equity
10 Years:	14%
5 Years:	11%
3 Years:	13%
Last Year:	13%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Sep 2026
Equity Capital	53	53	53	53	51	51	51	51	51	51	51	51	51
Reserves	474	750	858	1,032	1,157	1,367	2,246	2,445	2,027	2,134	2,287	2,394	2,624
	0	9	0	0	0	0	0	0	0	9	14	11	0
	91	64	81	73	57	53	112	135	127	134	150	134	151
Total Liabilities	619	875	992	1,159	1,266	1,471	2,409	2,632	2,205	2,329	2,503	2,590	2,826
	169	146	171	179	209	225	265	297	321	369	409	472	472
CWIP	2	0	0	0	0	3	6	0	0	1	0	2	2
Investments	299	605	732	913	1,001	1,133	2,047	2,208	1,754	1,786	1,900	1,974	2,223
	149	124	89	67	55	110	91	127	130	173	194	142	129
Total Assets	619	875	992	1,159	1,266	1,471	2,409	2,632	2,205	2,329	2,503	2,590	2,826

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	22	10	52	24	22	7	-2	-18	39	23	86	120
	5	-5	-47	-22	68	57	-35	19	7	26	-27	-54
	-25	-5	-5	-3	-89	-6	-15	-6	-46	-48	-58	-68
Net Cash Flow	2	-0	-0	-1	1	57	-52	-5	-0	0	1	-1
Free Cash Flow	22	11	38	14	-1	-15	-49	-51	14	-33	36	43
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	222%	172%	771%	245%	145%	246%	0%	-63%	112%	39%	109%	154%

Ratios

Consolidated / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	122	76	54	74	40	44	69	71	67	46	49	49
Inventory Days	880	659	438	247	289	411	2,112	2,885		3,694		1,161
Days Payable	200	144	128	125	202	151	693	640		1,237		530
Cash Conversion Cycle	801	591	364	195	126	305	1,488	2,316	67	2,502	49	679
Working Capital Days	235	172	39	20	13	22	97	223	118	77	57	-6
ROCE %		4%	4%	4%	4%	7%	1%	4%	4%	5%	7%	6%

Insights

In beta

Mar 2016

Mar 2017

Mar 2020

Mar 2021

Sep 2022

Mar 2025

Mar 2026

Stake in Alembic Pharmaceuticals Limited
% ・Standalone data

xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
xx	x	x	x		x
xxx	xxx	xxx	xxx		xxx
x	x	x	x		x
xxx	xxx				xxx	xxx
					xxx
x.xx	x.xx

Please log in to see hidden values.

Co-generation power installed capacity
MW ・Standalone data

Land bank
acres ・Standalone data

Wind power installed capacity
MW ・Standalone data

Permanent workforce
count ・Standalone data

Real estate project bookings
% ・Standalone data

R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

17 Recently

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
	70.88%	70.88%	70.88%	70.88%	70.88%	70.88%	70.88%	70.88%	70.88%	70.88%	70.88%	71.40%
	0.89%	1.07%	1.42%	1.97%	1.78%	1.65%	1.50%	1.38%	1.29%	1.25%	1.25%	1.34%
	0.04%	0.04%	0.04%	0.08%	0.06%	0.05%	0.05%	0.05%	0.05%	0.05%	0.06%	0.05%
	28.17%	28.02%	27.66%	27.07%	27.27%	27.41%	27.57%	27.68%	27.78%	27.81%	27.82%	27.20%
No. of Shareholders	94,012	99,130	98,478	1,02,249	1,07,423	1,06,732	1,07,510	1,06,470	1,04,103	1,02,008	1,01,238	1,00,706

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Sep 2026
	65.77%	63.71%	64.57%	67.62%	70.88%	70.88%	70.88%	70.88%	70.88%	70.88%	71.40%
	5.60%	1.16%	1.04%	1.80%	1.60%	1.12%	0.70%	1.07%	1.65%	1.25%	1.34%
	0.09%	5.35%	5.81%	5.94%	4.34%	4.69%	3.94%	0.04%	0.05%	0.05%	0.05%
	0.00%	0.67%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	28.54%	29.11%	28.58%	24.64%	23.18%	23.31%	24.48%	28.02%	27.41%	27.81%	27.20%
No. of Shareholders	56,623	66,838	61,605	53,132	67,238	80,135	82,339	99,130	1,06,732	1,02,008	1,00,706

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Alembic Ltd

Alembic Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings